Share on StockTwits

Equities research analysts at Jefferies Group increased their price target on shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) from $54.00 to $57.00 in a research note issued to investors on Wednesday. Jefferies Group’s price objective suggests a potential upside of 13.98% from the company’s current price.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded down 2.44% on Wednesday, hitting $48.79. The stock had a trading volume of 106,286 shares. Integra LifeSciences Holdings Corp. has a one year low of $37.39 and a one year high of $50.25. The stock’s 50-day moving average is $47.35 and its 200-day moving average is $46.34. The company’s market cap is $1.589 billion.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.68 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.64 by $0.04. The company had revenue of $231.40 million for the quarter, compared to the consensus estimate of $229.32 million. During the same quarter last year, the company posted $0.60 earnings per share. Integra LifeSciences Holdings Corp.’s revenue was up 12.6% compared to the same quarter last year. On average, analysts predict that Integra LifeSciences Holdings Corp. will post $2.95 earnings per share for the current fiscal year.

In other Integra LifeSciences Holdings Corp. news, Director Stuart Essig sold 50,800 shares of the company’s stock on the open market in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $47.76, for a total value of $2,426,208.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

Separately, analysts at Zacks reiterated a “neutral” rating on shares of Integra LifeSciences Holdings Corp. in a research note on Thursday, July 3rd. They now have a $50.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $52.00.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is an integrated medical technology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.